Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
January 2018
-
Media ReleaseSandoz announces exclusive global collaboration with Biocon on next-generation biosimilarsCollaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon…
-
Media ReleaseNovartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCLFiling acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted…
-
Media ReleaseAveXis Announces Pricing of Public Offering of Common StockCHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering…
-
Media ReleaseAveXis Announces Proposed Public Offering of Common StockCHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its…
-
Media ReleaseAveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy– Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of…
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patientsResults from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
-
Media ReleaseSandoz regulatory submission for proposed biosimilar adalimumab accepted by FDAAdalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
-
Key ReleaseNovartis appoints Elizabeth Barrett as Oncology HeadNovartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development…
-
Key ReleaseNovartis ernennt Elizabeth Barrett zur Chefin OnkologieNovartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug…
-
Media ReleaseNovartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial…
-
Media ReleaseREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyAveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control…
-
Organic dealmaker for drug discovery
New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.
Pagination
- ‹ Previous page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- …
- 151
- › Next page